SEATTLE, WASHINGTON--(Marketwire - March 29, 2012) - VentriPoint Diagnostics Ltd. (TSX VENTURE:VPT) (PINKSHEETS:VPTDF) is pleased to announce that it has received CE Approval for the Company's new Pulmonary Arterial Hypertension (PAH) application for the VentriPoint Medical System™ (VMS™). Easier than Magnetic Resonance Imaging (MRI) and safer than catheterization, without sacrificing accuracy, this application enables repeated monitoring of the right ventricle that ensures patients receive appropriate treatment. Sales and marketing of the PAH application in Europe will commence immediately.

Dr. Robyn Barst, Professor Emeritus of Pediatrics in Medicine at Columbia University College of Physicians & Surgeons and a member of the VentriPoint Scientific Advisory Board states, "Assessment of right ventricular (RV) function is essential for the management of patients with Pulmonary Arterial Hypertension." Furthermore, "To date, cardiac catheterization and cardiac MRI are the "gold standard" for invasive and non-invasive assessment of the RV in PAH. The novel non-invasive VMS technique provides accurate measurement of RV volumes and RV function in PAH (not feasible utilizing the currently available 2D and 3D echocardiographic imaging). This novel technique should prove useful in assessing efficacy with therapeutic interventions in patients with PAH."

VentriPoint's VMS heart analysis system is fast, accurate and non-invasive. The VMS technique benefits patients who cannot lie flat for up to an hour to undergo an MRI; patients with severe PAH must lie at an angle or sit up to avoid fluid buildup in their lungs. Furthermore, when using the VentriPoint system there is no need for catheterization, an invasive and frequently risky procedure.

"Securing approval to market our PAH application in Europe is an important milestone for the Company. I am very pleased that we can respond to growing demand among prospective customers in the European markets," said Dr. George Adams, President and CEO of VentriPoint.

About Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension, the most serious form of the five recognized groups of pulmonary hypertension, is a devastating disease with an average patient lifespan of less than 3 years after diagnosis if untreated. It affects individuals from infancy to the elderly. Although treatment started early after detection appears more effective than when started later, the majority of patients with PAH continue to be diagnosed too late for treatment to be fully effective. PAH can occur for no known reason but will typically occur in association with many common conditions such as chronic liver disease and liver cirrhosis; connective tissue disorders such as scleroderma or systemic lupus erythematosus (lupus); congenital heart disease (even if repaired) and HIV. With increasing availability of effective therapies, and evidence-based treatment guidelines recommending starting treatment early, tests enabling detection as early as possible should prove invaluable.

About VentriPoint Diagnostics Ltd.

VentriPoint has created a diagnostic ultrasound tool to monitor patients with heart disease, a leading cause of death in developed countries. Management believes the VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application in a suite of applications for all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure, which management believes has a multibillion-dollar market potential. Canada and Europe (CE Mark) have granted approval for the sale of VentriPoint's VMS™ heart analysis system and VentriPoint is pursuing the US-FDA approval through the 510(k) process.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward- looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by applicable securities laws, the Corporation does not assume any obligation to update or revise them to reflect new events or circumstances. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.